



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, September 13, 2018, 2:00pm
DMAS 7A Conference Room
Agenda

1. **Call to Order and Introductions** – Bill Rock, PharmD, Chair
2. **Minutes** - Approval of Minutes from May 10, 2018 meeting
3. **DMAS' vision for DUR Board and By-Law Changes** – Dr. Kate Neuhausen, CMO recommendations and comments
4. **Lab Data Demonstration** – Annette Paul, RPh
5. **RetroDUR Criteria Estimates** – Annette Paul, RPh
6. **Prior Authorization Consensus Statement** – Wendy Nash, PharmD
7. **New Drugs - Grid**
 - a. Aimovig™ (ereumab-aooe)
 - b. Cimduo™ (lamivudine and tenofovir disoproxil fumarate)
 - c. Jynarque® (tolvaptan)
 - d. Osmolex ER™ (amantadine)
 - e. Palynziq™ (pegvaliase-pqpz)
 - f. Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate)
 - g. Tavalisse™ (fostamatinib disodium hexahydrate)
 - h. Yonsa® (abiraterone acetate)
 - i. Drug Updates: New Generics; New Dosage Form or Strength; PDL-Eligible; SA form updates.



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

- 8. Physician-Administered Drugs**
 - a. Avastin® (bevacizumab)
 - b. Kymriah™ (tisagenlecleucel)
 - c. Nucala® (mepolizumab)
 - d. Spinraza®(nusinersen)
 - e. Xolair® (Omalizumab)
- 9. Specialty Drugs**
- 10. Topics for Discussion**
 - a. Analysis of Compounded Medications
 - a. Acute Dosing of Proton Pump Inhibitors
 - b. Pediatric and Adult Opioid Utilization
 - c. Naloxone Utilization Review
 - d. Synagis
 - e. DUR Quarterly Newsletter
- 11. Reports**
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
- 12. Adjournment**